Blackstone Labs

Super-DMZ RX 2.0

F
N+ Score46
Vitamins & MineralsServing: 1 Capsule(s)Type: Non-Nutrient/Non-Botanical

Super-DMZ RX 2.0 from Blackstone Labs is categorized as a 'Non-Nutrient/Non-Botanical' supplement, focusing on specific synthetic compounds. Each capsule contains 10 mg of 2a, 17a-dimethyl-17b-hydroxy-5a-androst-1-en-3-one and 10 mg of 17 beta-hydroxy 2 alpha,17beta-dimethyl 5 alpha-androstan 3-one azine. The product has an N+ Score of 46, earning it an F grade and placing it in the below-average tier. This score reflects concerns regarding the nature of the ingredients, which are synthetic and not typically found in conventional dietary supplements, and may carry significant risks. The product's formulation does not align with the safety and efficacy standards typically associated with well-regarded dietary supplements. It is not recommended for general use due to the nature of its active ingredients.

About This Product

Super-DMZ RX 2.0 by Blackstone Labs is a vitamins & minerals supplement containing 2 active ingredients. It has earned an N+ Score of 46/100 (Grade F).

N+ Score Breakdown

Ingredient Adequacy50/100

Are key ingredients present at clinically effective doses based on research?

Formula Completeness0/100

Does the product include all expected ingredients for its supplement category?

Label Transparency100/100

Are individual ingredient amounts clearly disclosed without proprietary blends?

Ingredient Diversity42/100

Does the formula include a breadth of beneficial compounds from multiple pathways?

Strengths

  • +Fully transparent label with individual ingredient amounts disclosed

Weaknesses

  • −Missing several expected ingredients for its category

Ingredient Analysis (2 ingredients)

IngredientAmountDose Adequacy
2a, 17a-dimethyl-17b-hydroxy-5a-androst-1-en-3-one10.000 mgN/A
17 beta-hydroxy 2 alpha,17beta-dimethyl 5 alpha-androstan 3-one azine10.000 mgN/A

Clinical ranges based on NIH ODS Fact Sheets and peer-reviewed research. Status indicates whether the amount meets evidence-based thresholds.